The performance research programme
Read the evidence.
Peptide research for athletes and lifters. Clear evidence. Visible limits.
Find your research lane
Choose your research lane
Muscle growth: measure more than mass.
Growth-hormone signalling, body composition and the evidence gap between lean mass and lifting performance.
Research briefRecovery: the function comes first.
BPC-157, TB-500 and the repair literature, with tissue-specific questions and honest recovery limits.
Research briefA cut has more than one outcome.
Body-composition research during energy restriction, including AOD-9604, GH claims and the limits of a twelve-week cut.
Research briefDurability begins with the workload.
Injury-prevention research, connective tissue, load management, warm-ups and the limits of preventive peptide claims.
Research briefCycling theory is not a reset button.
Receptor desensitisation, hormone feedback, continuous-use claims and the uncertainty behind peptide cycles.
Research briefThe rules run all year.
WADA substance restrictions, NCAA and federation policies, detection limits and the difference between tested and untested sport.
The setting changes the story.
A result in a dish can explain a mechanism. A change in a blood marker can show a drug response. Neither automatically means more strength, a healed tendon or a safer training block. This library keeps those findings separate.
Seven profiles. Seven different evidence bases.
The compounds are often discussed as one category. Their research settings, formulations and unanswered questions differ. Use this index to choose a profile, then read its limits alongside its mechanism.
| Compound | Research focus | Evidence to keep in view |
|---|---|---|
| BPC-157 | Tendon, ligament and gut repair | Predominantly animal and laboratory work |
| TB-500 | Cell migration and tissue repair | Much of the cited work concerns full-length thymosin beta-4 |
| CJC-1295 + ipamorelin | Growth-hormone signalling | Human pharmacology is not a tested lifting programme |
| Sermorelin | GHRH receptor signalling | Clinical context differs from athletic enhancement |
| AOD-9604 | Fat-metabolism research | Mechanism does not establish reliable athletic fat loss |
| GHK-Cu | Skin and tissue-remodelling research | Topical, cell and systemic findings are different |
| Epithalon | Telomerase and ageing research | Cell-level findings do not establish a longer athletic career |
Read with a training log in mind.
Ask what was measured, in whom, over what period and against which comparison. “Lean mass” is not the same as muscle strength; less soreness is not the same as repaired tissue; a purity result is not the same as clinical safety.
For tested athletes, the starting line is competition eligibility. For a first look at the literature, start with the reading checklist. Our editorial method explains how sources and corrections are handled.
The next lap
A first read, before a first cycle.
A plain-language checklist for reading CJC-1295, ipamorelin and peptide research without personal-use instructions.
Research briefThe timeline is not the result.
How to read peptide outcome claims, separate biomarkers from performance and assess timelines without forecasts.
Vendor reviewThe vendor scorecard.
The Athlete Vendor Stack Score retains its May 2026 ranking, with verified October 2026 Oath facts and clear methodology limits.